Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Free Cash Flow (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Free Cash Flow for 14 consecutive years, with -$9.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 26.04% year-over-year to -$9.2 million, compared with a TTM value of -$27.9 million through Dec 2025, down 18.26%, and an annual FY2025 reading of -$27.9 million, down 15.16% over the prior year.
  • Free Cash Flow was -$9.2 million for Q4 2025 at Heron Therapeutics, down from $1.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $2.9 million in Q3 2024 and bottomed at -$63.3 million in Q2 2021.
  • Average Free Cash Flow over 5 years is -$23.3 million, with a median of -$18.8 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 129.48% in 2024, while the deepest fall reached 663.17% in 2024.
  • Year by year, Free Cash Flow stood at -$45.6 million in 2021, then rose by 16.87% to -$37.9 million in 2022, then soared by 105.81% to $2.2 million in 2023, then plummeted by 663.17% to -$12.4 million in 2024, then increased by 26.04% to -$9.2 million in 2025.
  • Business Quant data shows Free Cash Flow for HRTX at -$9.2 million in Q4 2025, $1.3 million in Q3 2025, and -$11.1 million in Q2 2025.